Recombinant Human CD47 Protein, Llama IgG2b Fc Tag, low endotoxin, 100 µg

Background
Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is very broadly distributed on normal adult tissues. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation.

Source
Recombinant human CD47, Llama IgG2b Fc Tag, low endotoxin (CD7-H5251) is expressed from human 293 cells (HEK293). It contains AA Gln 19 - Pro 139 (Accession # Q08722-3).
Predicted N-terminus: Gln 19

Molecular Characterization
This protein carries a llama IgG2b Fc tag at the C-terminus.
The protein has a calculated MW of 41.6 kDa. The protein migrates as 60-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 0.01 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20^°C to -70^°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to poduct data sheet.

Clinical and Translational Updates

(1) "Aryl azoles based scaffolds for disrupting tumor microenvironment"
Pla-López, Martínez-Colomina, Cañada-García et al
Bioorg Med Chem (2023) 95, 117490
(2) "Genome-wide analysis revealed the dysregulation of RNA binding protein-correlated alternative splicing events in myocardial ischemia reperfusion injury"
Ma, Xu, Zhang et al
BMC Med Genomics (2023) 16 (1), 251
(3) "Biomimetic Nanocarriers of Pro-Resolving Lipid Mediators for Resolution of Inflammation in Atherosclerosis"
Anghelache, Voicu, Deleanu et al
Adv Healthc Mater (2023)
Showing 1-3 of 2534 papers.